帕博利珠单抗治疗MSI-H/dMMR晚期结直肠癌的疗效和安全性

1文献来源 Le D T,Kim T W,Van Cutsem E,et al.Phase Ⅱopen-label study of pembrolizumab in treatment-refractory,microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer:KEYNOTE-164[J].J Clin Oncol,2019,38(1):11-19. 2证据水平 2a. 3背景 ?微卫星高度不稳定性(microsatellite instability high,MSI-H)或错配修复功能缺陷(mismatch repair-deficient,dMMR)结直肠癌患者的预后比微卫星稳定(microsatellite stability,MSS)结直肠癌患者的预后差. ?有证据表明,程序性死亡配体1(programmed cell death-ligand 1,PD-L1)拮抗剂或合并细胞毒性T淋巴细胞相关抗原4(cytotoxic T lymphocyte-associated antigen-4,CTLA4)抑制剂对MSI-H/dMMR实体瘤患者具有抗肿瘤活性.